Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 40

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 40
---
 exceeded its updated fair value.

NOTE 9—ACCRUED EXPENSES

Accrued expenses consist of the following (in thousands): December 31, 20242023Accrued selling, general and administrative expenses$15,622 $12,811 Accrued research and development expenses4,501 5,141 Accrued cost of goods sold8,411 10,180 Other accrued operating expenses9,301 3,953 Compensation and benefits28,811 21,682 Accrued royalties1,451 561 Accrued interest1,418 1,389 Product returns and wholesaler service fees10,609 8,526 Total$80,124 $64,243 

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-22

Table of ContentsPACIRA BIOSCIENCES, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

NOTE 10—DEBT

The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):December 31,20242023Term loan A facility maturing March 2028$104,211 $115,202 2.125% Convertible senior notes due May 2029279,334 — 0.750% Convertible senior notes due August 2025201,776 398,594 3.375% Convertible senior notes due May 2024 (1)— 8,641      Total$585,321 $522,437 (1) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.2028 Term Loan A FacilityOn March 31, 2023, the Company entered into a credit agreement (as amended and/or restated to date, the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders, to refinance the indebtedness outstanding under the Company’s then-existing TLB Credit Agreement (as defined and discussed below). The term loan issued under the TLA Credit Agreement (the “TLA Term Loan”) was issued at a 0.30% discount and provides for a single-advance term loan A facility in the principal amount of $150.0 million, which is secured by substantially all